Veru Inc. announced that its Chief Scientific Officer will present new results from a Phase 2b study analyzing the effects of enobosarm combined with GLP-1 receptor agonists on physical function and weight loss in older obese patients. The data, from the QUALITY study, show enobosarm helps preserve lean mass and improve fat loss when used with semaglutide. Veru is also advancing a Phase 2b PLATEAU trial to further evaluate enobosarm's ability to enhance weight loss and physical function in patients aged 65 and older. Additionally, Veru is developing sabizabulin for metastatic pancreatic cancer, aiming to start a Phase 2b trial after FDA discussions in late 2026.
Veru's clinical study updates come as the health sector on Pluang shows strong market breadth, with 121 of 150 US health stocks rising today. For readers following health stocks, here is Pluang's market snapshot as of Nov 09, 2026 19:41 WIB: Immunovant Inc. (IMVT) gained 9.73% to USD 33.50 with a typical hold time of 17 days, Inovio Pharmaceuticals Inc. (INO) rose 8.64% to USD 1.32 with a 41-day hold, and Cassava Sciences Inc. (FLNA) increased 5.94% to USD 0.48 with a 39-day hold. Overall, the sector showed robust positive momentum.
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
